This technology leverages microparticles encapsulating mesenchymal stem cell (MSC) conditioned media to mimic the secretion of bioactive factors by MSCs
Description
The invention aims to provide a consistent and controlled release of these factors, addressing significant challenges in drug delivery and tissue engineering. The potential impact of this invention includes improved therapeutic outcomes, reduced immunological concerns, and enhanced practicality and cost-effectiveness in clinical applications.
Applications
• Cardiovascular
• Immunology
• Orthopedics
• Regenerative Medicine
Advantages
Traditional drug delivery systems struggle with the consistent release of multiple bioactive factors, often resulting in suboptimal therapeutic outcomes. Artificial MSCs overcome this by utilizing highly-porous microparticles that enable the simultaneous and sustained release of multiple factors. This technology also eliminates the need for autologous cells, which can be impractical and costly to obtain, especially from diseased populations. Additionally, artificial MSCs can be produced in large quantities and stored for future use, making them ideal for emergency situations and reducing the time required for treatment preparation.
Invention Readiness
The current state of the technology is at the in vitro data stage, demonstrating the feasibility of the artificial MSCs in controlled environments. The next steps involve further validation through preclinical and clinical trials to establish safety and efficacy in human applications. The development of scalable manufacturing processes and regulatory approvals will also be critical to bringing this technology to market. Continued research and collaboration with industry partners will be essential to advance the readiness of this invention.
IP Status
https://patents.google.com/patent/US20230285290A1
